SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Encouraging early zugo-cel data in autoimmune diseases is drawing attention: traders highlight responses in systemic sclerosis and inflammatory myopathy, alongside a favorable initial safety read across 21 patients. Bulls see promise in the off-the-shelf CD19 CAR-T approach, while others stress that the small cohorts and early follow-up leave efficacy and safety to be confirmed.

iShares Inc. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

EWY is rebounding with South Korean equities and memory-chip stocks after a sharp AI-related selloff and forced deleveraging. Traders are debating whether the bounce signals stabilization or is temporary, with KOSPI volatility keeping sentiment cautious.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc

Discussion is fragmented, with the most common theme being swings in the broader Nasdaq and tech market: traders debate whether selloffs will deepen or give way to a rebound. Company-specific posts also point to recent quarterly results and Nasdaqs planned extended-hours trading, but neither clearly dominates the conversation.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus clinical pipeline: traders are watching for further REGAIN glioblastoma data, updates from the completed-enrollment IMPACT pancreatic trial, ReSTART results, and a possible FDA IDE for the Keytruda combination. The community is broadly bullish on the upcoming milestones and recent share-price strength, though some are waiting for confirmed updates rather than speculating about the next announcement.

Litecoin (LTC) is a cryptocurrency . Users are able to generate LTC through the process of mining. Litecoin has a current supply of 84,000,000 with 77,805,873.7130931 in circulation. The last known price of Litecoin is 52.00804602 USD and is down -0.75 over the last 24 hours. It is currently trading on 1567 active market(s) with $117,565,973.29 traded over the last 24 hours. More information can be found at https://litecoin.org/.

Litecoin

Litecoins pullback and weak performance after earlier rallies are driving discussion, with traders parsing technical support and some treating the decline as an accumulation opportunity. Others argue LTC repeatedly gives back gains and may remain under pressure, while bullish breakout and squeeze calls remain speculative.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTechs quarterly results and raised full-year revenue guidance are drawing attention, alongside progress in its cancer pipeline as COVID-related revenue wanes. Traders see the update as support for its oncology transition, while others remain cautious about clinical execution and compare its performance unfavorably with Moderna.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AIs quarterly results beat expectations and the company raised its full-year revenue outlook, prompting a bullish reaction and heavy focus on call-option activity. Traders are debating whether momentum will continue or fade, while some remain cautious about volatility, valuation, and how quickly hospitals will adopt its AI products.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zoom is drawing attention ahead of earnings, with traders debating whether its AI products can drive new growth as rivals bundle similar meeting tools and companies trim paid seats. Skeptics see a mature, low-growth business with limited upsell potential, while others are watching the $90 level for a technical rebound.

Dow, Inc. is a holding company, which engages in the development of innovative solutions. It operates through the following segments: Packaging and Specialty Plastics, Industrial Intermediates and Infrastructure, and Performance Materials and Coatings. The Packaging and Specialty Plastics segment consists of hydrocarbons and energy and packaging and specialty plastics. The Industrial Intermediates and Infrastructure segment covers the industrial solutions and polyurethanes, and construction of chemicals. The Performance Materials and Coatings segment includes coatings and performance monomers, and consumer solutions. The company was founded in 1897 and is headquartered in Midland, MI.

Dow Inc

Unusual options and elevated dark-pool activity are drawing attention, with traders noting fresh positioning on both calls and puts and debating whether the put flow reflects hedging or a bearish view. The broader discussion is directionally mixed, with some traders expecting further weakness and others watching for a rebound.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Attention centers on povetacicepts upcoming FDA decision for IgA nephropathy, following positive Phase 3 RAINIER results; traders are bullish on its potential as a new growth pillar, though approval and commercial upside remain uncertain. Q3 results also drew mixed reactions, with revenue growth and raised guidance weighed against an adjusted EPS miss and concerns about valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders?

Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders? Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 4, 2026 Insiders may stand to receive...

Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?

Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders? Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, April 9, 2026 Insiders may stand to...

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--CYCN, CECO, THR, and CWAN

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--CYCN, CECO, THR, and CWAN $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--CYCN, CECO, THR, and CWAN...

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of...

CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) and Korsana Biosciences, Inc. Upon closing of the proposed transaction...

Globalstar, Exxon Mobil, Cyclerion Therapeutics, Eli Lilly And Intel: Why These 5 Stocks Are On Investors' Radars Today

GSAT, XOM, CYCN, LLY, INTC were among the stocks seen trending on Wednesday, April 1, 2026.read more...

Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders

Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders Shareholder Alert: Ademi LLP investigates whether Cyclerion...

Promising Medical Stocks To Consider - April 1st

Eli Lilly and Company, Cyclerion Therapeutics, Apellis Pharmaceuticals, UnitedHealth Group, Novo Nordisk A/S, Boston Scientific, and Johnson & Johnson are the seven Medical stocks to watch today...

Best Pharmaceutical Stocks To Follow Now - April 1st

Eli Lilly and Company, Cyclerion Therapeutics, Apellis Pharmaceuticals, Novo Nordisk A/S, and Pfizer are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool...

Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing

Cyclerion Therapeutics shares are trading sharply higher Wednesday morning after it announced a merger agreement with Korsana Biosciences.read more...

Korsana Biosciences, Inc. is a biopharmaceutical company, which engages in discovering and developing novel therapies to reduce the burden of neurodegenerative diseases. Its portfolio includes the KRSA-028 pipeline. The company was founded in 2024 and is headquartered in Waltham, MA.

Korsana Biosciences Inc.

CYCN Stock Is Soaring 274% Today — What Is Fueling The Rally?

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Korsana stated that it has secured $380 million in commitments from private investors to support the merger transaction.</li><li>The company added that its cash and cash equivalents balance at the closing of the transaction, including the funds from the private placement, is anticipated to fund the company’s operations into 2029.</li><li>Korsana expects the financing round to close immediately prior to the proposed merger.</li></ul>Cyclerion Therapeutics Inc. (CYCN) shares more than tripled in Wednesday’s opening trade, rallying by more than 274% after the company announced a deal with Korsana Biosciences Inc.Cyclerion stated that it has entered into a definitive merger agreement for an all-stock transaction. The merged entity will operate under the name Korsana Biosciences Inc., and trade on the Nasdaq under the ticker symbol ‘KRSA’.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/CYCN">Cyclerion Therapeutics</a> trended in the ‘neutral’ territory at the time of writing.<h2 class="st-heading-2">Korsana Secures $380M In Commitments To Support Merger</h2>Korsana stated that it has secured $380 million in commitments from private investors to support the merger transaction. The investment is led by Fairmount and Venrock Healthcare Capital Partners, with participation from General Atlantic, TCGX, Forbion, and Wellington Management, among others.The company expects the financing round to close immediately prior to the proposed merger.Korsana stated that its cash and cash equivalents balance at the closing of the transaction, including the funds from the private placement, is anticipated to fund the company’s operations into 2029, providing it with runway through key clinical milestones.“With our seasoned team and support from leading biotechnology investors, Korsana is well-positioned to advance a pipeline of innovative, next generation therapies,” said Korsana CEO Jonathan Violin.<h2 class="st-heading-2">What Does Korsana Do?</h2>Korsana is a Waltham, Massachusetts-based company that is engaged in the development of therapeutics to treat neurodegenerative diseases.Its lead program is KRSA-028, a next-generation shuttle antibody targeting amyloid beta for the treatment of Alzheimer’s disease, discovered in partnership with Paragon Therapeutics.KRSA-028 is designed to enhance amyloid plaque clearance, lower amyloid-related imaging abnormalities (ARIA) and hematologic risks, and improve convenience through low-volume subcutaneous delivery.<a href="https://stocktwits.com/symbol/CYCN">CYCN stock</a> is up 357% year-to-date and 128% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 19% over the past 12 months, while the Fidelity Nasdaq Composite Index ETF (ONEQ) is up 25%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ipm-bcg-hubc-stocks-top-premarket-gainers-april-1-2026/cZ7H1jsRInn">IPM, BCG, HUBC Among Stocks Soaring Before The Bell — Top Pre-Market Gainers Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Cyclerion stated that it has entered into a definitive merger agreement with Korsana Therapeutics in an all-stock transaction.

Cyclerion Therapeutics Inc

Fidelity Nasdaq Composite Index ETF

Vanguard Extended Market ETF

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$31.05
Prev Close	$30.43
Open	$29.82
Dividend Yield	0.00%
50-Day Moving Average	$31.40
Beta	0.31
Avg. Volume	139,470.17
PE Ratio	-2.37

52-Week High	$59.36
52-Week Low	$7.19
Market Capitalization	$1.41B
EPS (Annual)	-$7.76
Price to Book	3.61
Revenue Per Employee	$2.07M

Feed

News

Sentiment

Fundamentals

Info

CYCN Fundamentals